copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
A Study of Amivantamab Alone or in Addition to Other . . . - Janssen The purpose of this study is to determine safety and preliminary efficacy of amivantamab monotherapy, amivantamab in addition to pembrolizumab, amivantamab in addition to paclitaxel and amivantamab in addition to pembrolizumab and carboplatin in participants with recurrent metastatic head and neck cancer The study will also confirm the recommended Phase 2 combination dose (RP2CD) for
Home | Global Trial Finder What You Can Expect To Happen In A Clinical Trial Clinical trials are rarely the same They can last from weeks to years, study different doses of a medication, or even compare multiple medications at once While the details change, all trials are structured in a similar way Typically, there are four main parts of a trial, with each part serving a different purpose
Janssen We would like to show you a description here but the site won’t allow us
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ . . . The purpose of this study is to evaluate the efficacy of icotrokinra compared to placebo in biologic-experienced participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA
A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid . . . The purpose of Part 1 (Dose Escalation) of the study is to assess the effective dose (recommended Phase 2 dose [s] [RP2Ds]) that can be safely administered, and dosing regimens of JNJ-90189892 in participants with relapsed or refractory (R R) acute myeloid leukemia (AML) or R R higher-risk type of myelodysplastic neoplasms (type of cancer of the blood and bone marrow, which does not respond to
A Study of Milvexian in Participants After a Recent Acute . . . - Janssen The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major adverse cardiovascular event (MACE) (the composite of cardiovascular [CV] death, myocardial infarction [MI], and ischemic stroke)